Treatment of restenosis by controlled-release delivery systems of tyrphostins

Ilia Fishbein, Michael Chorny, Gershon Golomb*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Percutaneous transluminal coronary angioplasty (PTCA) procedures include balloon dilation, excisional atherectomy, endoluminal stenting, and laser ablation. However, despite significant advances in reducing the acute complications of percutaneous revascularization procedures with premedications and better techniques, chronic restenosis of dilated lesions remains a serious and frequent problem. The neointimal formation is dependent on smooth muscle cells and most probably fibroblast proliferation and migration mediated by various cytokines and growth factors. The unsuccessful attempts to control restenosis by systemic pharmacological interventions have prompted many researchers to look for more promising therapeutic approaches such as local drug delivery. In this review we discuss the rationale for local drug delivery based on restenosis pathophysiology, local drug delivery approaches, the rationale for antiproliferative therapy, and review the in vitro and in vivo studies of local drug delivery systems of tyrphostins (protein tyrosine kinase inhibitors) in restenosis therapy. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)487-496
Number of pages10
JournalDrug Development Research
Volume50
Issue number3-4
DOIs
StatePublished - 2000

Keywords

  • Angioplasty
  • Balloon injury
  • Controlled release
  • Drug delivery systems
  • PDGF
  • Protein tyrosine kinase
  • PTCA
  • Restenosis
  • Tyrphostins

Fingerprint

Dive into the research topics of 'Treatment of restenosis by controlled-release delivery systems of tyrphostins'. Together they form a unique fingerprint.

Cite this